On September 1, 3billion signed a Memorandum of Understanding (MoU) with Kolon Industries Future Technology Institute to expand their partnership in developing new gene therapy drugs.

3billion has been strengthening its in-house drug development capabilities based on its proprietary rare disease diagnosis database and artificial intelligence technology.

3billion and Kolon Industries plan on conducting preclinical verification of drug candidates discovered through an AI-driven drug development platform.

With its state-of-the-art R&D pipeline and experience conducting clinical trials, Kolon Industries Future Technology Institute is well-positioned to further expand its portfolio.

“Currently, there is no treatment for 95% of all rare genetic disorders. We will make every effort possible to develop a treatment for those suffering from these disorders through this partnership with Kolon Industries,” said Chang-won Keum, CEO of 3billion.

Do you want to keep up with the latest post of this series?